Model Predicts Cost-Effectiveness for Anal Lesion Treatment

This article originally appeared here.
Share this content:
Model Predicts Cost-Effectiveness for Anal Lesion Treatment
Model Predicts Cost-Effectiveness for Anal Lesion Treatment

MONDAY, Oct. 16, 2017 (HealthDay News) -- Cost-effective management of precancerous anal intraepithelial lesions in HIV-positive men who have sex with men (MSM) varies by age, according to a study published online Sept. 26 in Cancer.

Ashish A. Deshmukh, Ph.D., M.P.H., from the University of Florida in Gainesville, and colleagues constructed a decision analytic model for the natural history of anal carcinoma and high-grade squamous intraepithelial lesion (HSIL) management strategies for HIV-positive MSM aged ≥27 years.

The researchers found that active monitoring was the most effective approach in patients ≤29 years, with HSIL treatment plus adjuvant quadrivalent human papillomavirus (qHPV) vaccination becoming most effective in older patients. Doing nothing was cost-effective until 38 years of age; HSIL treatment plus adjuvant qHPV vaccination was cost-effective after the age of 38 years. The incremental cost-effectiveness ratio decreased as the age at HSIL management increased. The rate of HSIL regression or progression and the cost of high-resolution anoscopy and biopsy affected outcomes.

"The management of HSIL in HIV-positive MSM who are 38 years old or older with treatment plus adjuvant qHPV vaccination is likely to be cost-effective," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »